Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Research Partnership Seeks Compounds to Slow Loss of Motor Neurons in ALS

By BiotechDaily International staff writers
Posted on 01 Oct 2013
A renowned American research institute is collaborating with a German drug discovery company to identify compounds that can prevent or slow down the loss of motor neurons, which is characteristic of the human disease amyotrophic lateral sclerosis (ALS).

ALS is a debilitating disease that induces muscle weakness and atrophy throughout the body caused by the degeneration of the upper and lower motor neurons. The majority of ALS victims die within three to five years from the onset of the symptoms, and only about 10% survive for 10 years or more. The incidence of the syndrome is approximately two per 100,000 people, and there are about 150,000 diagnosed ALS patients worldwide.

Investigators at the Harvard Stem Cell Institute (Boston, MA, USA) will be working with colleagues at Evotec AG (Hamburg, Germany) in a strategic partnership dedicated to the identification of compounds able to prevent or slow down the loss of motor neurons in ALS. The collaboration, which is being called “CureMN” (CureMotorNeuron), will leverage human motor neuron assays based on ALS patient-derived induced pluripotent stem (iPS) cells that were developed by Harvard Stem Cell Institute researchers Dr. Lee Rubin and Dr. Kevin Eggan.

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies. Evotec has established an enviable position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology and inflammation.

Dr. Cord Dohrmann, CSO of Evotec, said, “Kevin and Lee have made significant contributions to our understanding of the underlying pathology of motor neuron diseases. Their laboratories have developed a large array of ALS patient-derived motor neuron models that allow screening of diseased human cells in culture – an approach that is sometimes referred to as a “clinical trial in a dish.” Our intention is to systematically screen for new mechanisms, targets, and compounds that have the potential to be developed into new products that will modify and ideally halt the progression of ALS and potentially other motor neuron diseases.”

Related Links:
Harvard Stem Cell Institute
Evotec AG



RANDOX LABORATORIES
BIOSIGMA S.R.L.
SLAS - Society for Laboratory Automation and Screening
comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: The Human Protein Atlas is tissue-based map of the human proteome (Photo courtesy of the Human Protein Atlas).

Open Source Tissue-Based Map of the Human Proteome Launched

Constructed with 13 million annotated images, an interactive database has been created to show the distribution of proteins in all major tissues and organs of the human body. Ten years after the completion... Read more

Drug Discovery

view channel

Omega 3 Found to Improve Behavior in Children with ADHD

Supplements of the fatty acids omega 3 and 6 can help children and adolescents who have a specific kind of have attention deficit hyperactivity disorder (ADHD). Moreover, these findings indicate that a customized cognitive training program can improve problem behavior in children with ADHD. Statistics show that 3%–6%... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Lab Technologies

view channel

e-Incubator Technology Provides Real-Time Imaging of Bioengineered Tissues in a Controlled Unit

A new e-incubator, an innovative miniature incubator that is compatible with magnetic resonance imaging (MRI), enables scientists to grow tissue-engineered constructs under a controlled setting and to study their growth and development in real time without risk of contamination or damage. Offering the potential to test... Read more

Business

view channel

Two Industry Partnerships Initiated to Fuel Neuroscience Research

Faster, more complex neural research is now attainable by combining technology from two research companies. Blackrock Microsystems, LLC (Salt Lake City, UT, USA), a developer of neuroscience research equipment, announced partnerships with two neuroscience research firms—PhenoSys, GmbH (Berlin, Germany) and NAN Instruments, Ltd.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.